Sign up Australia
Proactive Investors - Run By Investors For Investors

Living Cell Technologies files patent for neurological agent

The technology could reverse human brain neurodegenerative processes.
neural pathways
Identifying neuroprotective product candidates

Living Cell Technologies Ltd (ASX:LCT) has filed a provisional patent for pericyte (a type of cell) protective agents for neurological disorders including neurodegenerative and central nervous system diseases.

The invention in this provisional patent arises from Living Cell’s research collaboration with the Centre for Brain Research (CBR) at The University of Auckland.

The research collaboration explored how the company’s products can reverse human brain neurodegenerative processes associated with pericytes (and other brain cells).

Living Cell’s lead product, NTCELL®, is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells.

After implantation, NTCELL functions as a biological factory, producing factors to promote new central nervous system growth and repair disease-induced nerve degeneration.

The company is aiming to extend the pipeline for NTCELL by examining its effects on cell cultures derived from human brains with Alzheimer’s disease and Parkinson’s disease.

The filing of the new patent will enable Living Cell to build and extend its expertise on the efficacy of cell therapies which have the potential to treat neurodegenerative disorders.

Critically, the ability to generate data from human brain tissue cultures can potentially lead the company to identify neuroprotective product candidates.

View full LCT profile View Profile

Living Cell Technologies Ltd Timeline

Related Articles

hepatitisC.jpg
January 19 2018
Regulatory sign-off fires starting pistol on the commercial launch in Europe, Africa, EU Medical Devices Directive awarded CE IVD certification, molecular diagnostics, Europe, Africa, Sysmex
picture of genes
November 29 2017
Among those cited as using Silence’s tech is US firm Alnylam, valued at US$12.7bn.
newspaper with word cancer magnified
January 15 2018
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use